Among trials evaluating the efficacy of CDK4/6 inhibitors in patients with treatment-naïve HR+/HER2- advanced breast cancer, only PALOMA-2 included patients with brain metastases (2 of 666 enrolled participants), but only if they were previously treated and stable. This evidence concerns the gene ERBB2 and breast carcinoma.